Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

[1]  D. Paulson.  Impact of radical prostatectomy in the management of clinically localized disease. , 1994, The Journal of urology.

[2]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[3]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[4]  W. Catalona,et al.  5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. , 1994, The Journal of urology.

[5]  A. Partin,et al.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.

[6]  W. Catalona,et al.  Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. , 1994, The Journal of urology.

[7]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[8]  E. Jaffee,et al.  Demonstration of a rational strategy for human prostate cancer gene therapy. , 1994, The Journal of urology.

[9]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[10]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[11]  J. Simons,et al.  Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. , 1993, Cancer treatment reviews.

[12]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Humphrey,et al.  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. , 1993, The Journal of urology.

[14]  S. Larson,et al.  Therapeutic alternatives for hormone-refractory prostatic cancer. , 1992, Seminars in urology.

[15]  P. Walsh,et al.  Cancer control following anatomical radical prostatectomy: an interim report. , 1991, The Journal of urology.

[16]  J. Dekernion,et al.  Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. , 1991, British journal of urology.

[17]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[18]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[19]  G. Haas,et al.  Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy. , 1994, Urology.

[20]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[21]  Jonathan A. Cooper,et al.  Role of epidermal growth factor‐stimulated protein kinase in control of proliferation of A431 cells , 1982, Journal of cellular biochemistry.